|
|
 Synergy
analysis of "classic" and newer drug combinations.
Combination chemotherapy
frequently, but not always, has produced greater degrees of clinical benefit
than single agent therapy. There are two potential explanations for this.
Firstly, when two or more drugs are given, there is a greater probability
that at least one of the drugs will be active. Second, there is the potential
for true synergy, where the whole is greater than the sum of the parts.
|
 Cell
culture drug resistance testing predicts for patient survival in ovarian
cancer.
There have now
been 5 different studies of the relationship between the results of cell
culture drug resistance testing (CCDRT)and patient survival in ovarian
cancer, and all 5 studies show significant correlations between CCDRT and
patient survival.
|
Cell culture
drug resistance testing (CCDRT) improves patient survival in chemotherapy
of ovarian cancer.
30 years' worth
of prospective, randomized clinical trials based on attempting to identify
"best" one-size-fits-all treatment regimens have produced no
important progress in the chemotherapy of advanced (Stage III, IV, and
recurrent/refractory) ovarian cancer.
|
Current Status of Drug Restance Testing
Cell culture drug resistance testing (CCDRT) is purported to correlate with response
to chemotherapy and/or with patient survival after chemotherapy...
An extensive, diverse, and consistent literature documents the ability of cell death
assays to identify forms of chemotherapy which are associated with both favorable and
unfavorable prognoses.
( PDF format )
|
|
|
|
|
|
